Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Clinical trial NCT02814916 · COMPLETED

Trial details

NCT number: NCT02814916
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Methicillin-Resistant Staphylococcus Aureus Bacterial Infections Staphylococcal Skin Infections

Start date: 2017-03-30
Primary completion: 2024-01-01
Enrollment: 199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.